-
Mashup Score: 0
Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2
Objective To determine the risk of not being able to sustain remission after tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA). Methods A systematic literature search was conducted in MEDLINE, Embase, and the Cochrane Library for studies reporting remission outcomes after tapering MTX from targeted therapies in RA. Full-text articles and…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Research Article Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis 📰 https://t.co/Cf7xXlfgjg #rheumatoidarthritis #methotrexate #remission https://t.co/5h7h7R5W5z
-
-
Mashup Score: 1HCVAD Chemotherapy Treatment Regimen Shows Promise for Blastic Plasmacytoid Dendritic Cell Neoplasm - 1 year(s) ago
A retrospective study published in the journal Blood Advances found that hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone chemotherapy treatment (HCVAD) had higher rates of complete remission (CR) compared with other therapy regimens.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
A #study published in the journal, Blood Advances, found that hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone chemotherapy treatment (#HCVAD) had higher rates of complete #remission compared with other therapy regimens. https://t.co/oe67gzbrhB
-
-
Mashup Score: 0Is Remission Always Needed Before Transplant in AML? Study Says No, Could Mean Less Toxic Chemotherapy - 1 year(s) ago
Results from a phase 3 study of patients with acute myeloid leukemia (AML) are being presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Phase 3 study presented at #ASH22 challenges thinking on whether some patients with AML need complete #remission before allo-HCT: https://t.co/QGjQPURgcK https://t.co/xp6FQBSPiM
-
-
Mashup Score: 0Is Remission Always Needed Before Transplant in AML? Study Says No, Could Mean Less Toxic Chemotherapy - 1 year(s) ago
Results from the ASAP study are being presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Is #Remission Always Needed Before Transplant in #AML? Study Says No, Could Mean Less Toxic Chemotherapy @ASH_hematology #ASH22 @cityofhope @LLSusa https://t.co/tLulqETXr7 via @AJMC_Journal
-
-
Mashup Score: 1American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision - 2 year(s) ago
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent studies indicating that a higher threshold for the patient global assessment (PtGA) may improve agreement between the two sets of criteria, our goals were to externally validate a revision of the…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
@ACRheum @eular_org remission criteria for #rheumatoid #arthritis! The 2022 revision: Validation of the #Boolean Criteria including a 2cm PtGA cut-off Validation of the previously provisionally endorsed SDAI and CDAI cut-offs for #remission @Stiddyo https://t.co/JJbDAWYnSl https://t.co/ogg2XGZg68
-
-
Mashup Score: 0Criteria - 2 year(s) ago
Information and projects related to classification criteria for rheumatic diseases.
Source: www.rheumatology.orgCategories: Latest Headlines, RheumatologyTweet-
ICYMI. ACR/@eular_org revise #remission #criteria for #RA. The ACR/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision is an update of the manuscript that was published in 2011. View → https://t.co/bHfqZcd10a https://t.co/xxe2lOzCkH
-
-
Mashup Score: 3Lymphoma Action | Remission - 2 year(s) ago
Complete remission means that there’s no longer evidence of lymphoma in your body. Partial remission means that there’s less lymphoma in your body than there was before. On this page What is the aim of treatment for lymphoma? Complete remission Partial remission How long does remission last? Remission and your emotions Remission in lymphoma video
Source: Lymphoma ActionCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @LymphomaAction: Missed our recent webinar on #remission in #lymphoma? Watch the recording on our website: https://t.co/WwNwsfyTNX Hear…
-
-
Mashup Score: 0
The highly encouraging results of the small study may lead to a new therapeutic approach in lupus. However, long-term safety and efficacy need to be evaluated in a larger cohort.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy was able to eliminate #lupus symptoms and help 5 patients with severe lupus achieve remission. https://t.co/bjoj8GI3RE #Remission #Rheumatology
-
-
Mashup Score: 0Defining remission in systemic lupus erythematosus - 2 year(s) ago
Duane Peters from the Lupus Foundation of America interviews Professor Ronald van Vollenhoven from the Amsterdam University Medical Centers in the Netherlands and Dr Cynthia Aranow from the Feinstein
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
This month #podcast on #Defining #remission in #SLE #Lupus Dr. Peters from @LupusOrg interviews @ronfvv and Dr. Aranow to discuss the efforts of the #DORIS task force for a single definition of SLE remission https://t.co/JJLMumSsgh
-
Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete #remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results. https://t.co/xOBt95RgEU https://t.co/eajAtmbs3y